English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

Aberrantly methylated genes contribute to the landscape of epigenetic alterations in colorectal adenocarcinoma. The global CpG Island methylator phenotype (CIMP) and individually methylated genes are potential prognostic/predictive biomarkers. Research suggests an association between methylated  DCR1  (m DCR1 ) and lack of benefit with irinotecan (IFL) treatment. We assessed the association between  DCR1  methylation status and survival in patients receiving adjuvant fluorouracil/ leucovorin (5-FU/LV) or IFL. We analysed data from patients with stage III colon adenocarcinoma randomly assigned to adjuvant 5-FU/LV or IFL in CALGB 89803 (Alliance). The primary endpoint was overall survival (OS), and the secondary endpoint was disease-free survival (DFS). Using tumour sample DNA, we evaluated the association between survival,  DCR1  methylation status, and molecular subgroups ( BRAF, KRAS , mismatch repair status, CIMP status) using Kaplan–Meier estimator and Cox proportional hazard model. m DCR1  was observed in 221/400 (55%) colon cancers. Histopathologic features were similar between m DCR1  and unmethylated  DCR1  (un DCR1 ) colon cancers. There was no difference in OS ( p  = 0.83) or DFS ( p  = 0.85) based on  DCR1  methylation status. There was no association between methylation status and response to IFL . In patients with un DCR1  and  KRAS -wildtype tumours, those who received IFL had a nearly two-fold worse DFS compared to patients who received 5-FU/LV (HR = 1.85, 95% CI (0.97–3.53,  p  = 0.06). This relationship was not notable among other subgroups. In stage III colon cancer patients, m DCR1  status did not associate with response to irinotecan. Larger studies may suggest an association between the iridocene response and molecular subgroups.

epigenetics

Evaluation of methylated DCR1 as a biomarker for response to adjuvant irinotecan-based therapy in stage III colon cancer: cancer and leukaemia Group B 89803 (Alliance)